Skip to main content
. 2023 May 10;15(1):2208697. doi: 10.1080/19420862.2023.2208697

Figure 4.

An illustration using icons to represent protein, cell-based and vaccine therapeutics that target cancer cells expressing NKG2D ligands.

Schematic representation of therapeutic modalities targeting the MICA/B pathway.

(a) Protein-based therapeutics targeting the MICA/B pathway including an ADC that delivers a cytotoxic payload to MICA/B-expressing tumor cells, mAbs that induce immune-mediated tumor cell killing by preventing shedding of cell surface MICA/B or by binding to sMICA/B to form a NKG2D-activating complex, and a TriNKET that simultaneously binds NKG2D and CD16A on NK cells and targets Her2-expressing tumor cells. (b) Allogeneic or autologous NKG2D based r CAR)T-cell therapies activated by NKG2D ligands including MICA/B and (c) an allogeneic NKG2D based CAR NK cell therapy and iPSC-derived allogeneic MICA/B scFV-based CAR NK cell therapy activated by NKG2D ligands including MICA/B. (d) Vaccine-induced production of antibodies targeting the MICA/B alpha 3 domain.